Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Decatur Memorial Hospital Cancer Care Institute
mi
from
Decatur, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
CCOP - Evanston
mi
from
Evanston, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
CCOP - Evanston
mi
from
Evanston, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Ingalls Cancer Care Center at Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Oncology/Hematology Associates of Central Illinois, P.C.
mi
from
Peoria, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Oncology/Hematology Associates of Central Illinois, P.C.
mi
from
Peoria, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated:  7/22/2015
Margaret and Charles Juravinski Cancer Centre
mi
from
Hamilton,
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase II Study of PS-341 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter, and Renal Pelvis)
Status: Enrolling
Updated: 7/22/2015
Margaret and Charles Juravinski Cancer Centre
mi
from
Hamilton,
Click here to add this to my saved trials
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin
mi
from
Madison, WI
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
Phase I Study of a DNA-based Vaccine Targeting Prostatic Acid Phosphatase (PAP) in Patients With Stage D0 Prostate Cancer
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Thoracic OncoGeriatric Assessment (TOGA) Trials
Preoperative Oncogeriatric Assessment for Thoracic Malignancies
Status: Enrolling
Updated:  7/22/2015
University of Wisconsin Hospital
mi
from
Madison, WI
Thoracic OncoGeriatric Assessment (TOGA) Trials
Preoperative Oncogeriatric Assessment for Thoracic Malignancies
Status: Enrolling
Updated: 7/22/2015
University of Wisconsin Hospital
mi
from
Madison, WI
Click here to add this to my saved trials
STAT3 DECOY in Head and Neck Cancer
Preliminary Assessment of the Safety and Biological Activity of Intratumoral STAT3 DECOY in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated:  7/22/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
STAT3 DECOY in Head and Neck Cancer
Preliminary Assessment of the Safety and Biological Activity of Intratumoral STAT3 DECOY in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Status: Enrolling
Updated: 7/22/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases
Status: Enrolling
Updated:  7/22/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases
Status: Enrolling
Updated: 7/22/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
FACBC PET/CT for Recurrent Prostate Cancer
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).
Status: Enrolling
Updated:  7/23/2015
Emory University Hospital
mi
from
Atlanta, GA
FACBC PET/CT for Recurrent Prostate Cancer
18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).
Status: Enrolling
Updated: 7/23/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma
Status: Enrolling
Updated:  7/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma
Status: Enrolling
Updated: 7/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bladder Cancer Patient-Reported Outcomes
A Cross-Sectional Study Of Patient-Reported Outcomes For Bladder Cancer Patients With Non-Invasive Disease
Status: Enrolling
Updated:  7/23/2015
Baylor College of Medicine
mi
from
Houston, TX
Bladder Cancer Patient-Reported Outcomes
A Cross-Sectional Study Of Patient-Reported Outcomes For Bladder Cancer Patients With Non-Invasive Disease
Status: Enrolling
Updated: 7/23/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated:  7/23/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated: 7/23/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated:  7/23/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated: 7/23/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated:  7/23/2015
Nebraska Cancer Specialists
mi
from
Omaha, NE
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated: 7/23/2015
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated:  7/23/2015
MUSC Hollings Cancer Center
mi
from
Charleston, SC
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153
Status: Enrolling
Updated: 7/23/2015
MUSC Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
Sentinel Lymph Node Mapping Post-Injection Site Pain
A Randomized, Double-blinded, Controlled Clinical Trial Comparing Post-injection Site Pain of Technetium-labeled Tilmanocept Versus Technetium-labeled Sulfur Colloid in Patients Undergoing Sentinel Lymph Node Mapping Procedure for Breast Cancer
Status: Enrolling
Updated:  7/23/2015
University of California, San Diego
mi
from
San Diego, CA
Sentinel Lymph Node Mapping Post-Injection Site Pain
A Randomized, Double-blinded, Controlled Clinical Trial Comparing Post-injection Site Pain of Technetium-labeled Tilmanocept Versus Technetium-labeled Sulfur Colloid in Patients Undergoing Sentinel Lymph Node Mapping Procedure for Breast Cancer
Status: Enrolling
Updated: 7/23/2015
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Massachusetts General Hospital
mi
from
Boston, MA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Boston University Cancer Research Center
mi
from
Boston, MA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
William Beaumont Hospital - Royal Oak Campus
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Stony Brook University Cancer Center
mi
from
Stony Brook, NY
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Stony Brook University Cancer Center
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Good Samaritan Hospital Cancer Treatment Center
mi
from
Cincinnati, OH
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Good Samaritan Hospital Cancer Treatment Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
H. Clay Evans Johnson Cancer Center at Memorial Hospital
mi
from
Chattanooga, TN
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
H. Clay Evans Johnson Cancer Center at Memorial Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Medical City Dallas Hospital
mi
from
Dallas, TX
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Medical City Dallas Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/23/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Pilot Study of Radiofrequency Ablation in High-Risk Patients With Stage IA Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/23/2015
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Status: Enrolling
Updated:  7/23/2015
Clinical Research Facility
mi
from
San Antonio, TX
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Status: Enrolling
Updated: 7/23/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy
A Prospective, Single Center, Observational Study Comparing the Safety and Efficacy of CVATS, HVATS and Open Surgery for Subjects Diagnosed With NSCLC Scheduled to Undergo a Lobectomy
Status: Enrolling
Updated:  7/23/2015
New York University School of Medicine
mi
from
New York, NY
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy
A Prospective, Single Center, Observational Study Comparing the Safety and Efficacy of CVATS, HVATS and Open Surgery for Subjects Diagnosed With NSCLC Scheduled to Undergo a Lobectomy
Status: Enrolling
Updated: 7/23/2015
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated:  7/24/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
A Phase I, Open-Label, Multicenter, Dose-Escalation Study of the Safety and Pharmacokinetics of a Recombinant Humanized Antibody to Her2 (rhuMAb 2C4) Administered Every 3 Weeks to Subjects With Advanced Solid Malignancies
Status: Enrolling
Updated: 7/24/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated:  7/25/2015
Ohio State University-Division of Gyn Oncology
mi
from
Columbus, OH
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status: Enrolling
Updated: 7/25/2015
Ohio State University-Division of Gyn Oncology
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303)
Status: Enrolling
Updated:  7/27/2015
Baylor Breast Center
mi
from
Houston, TX
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
A Neoadjuvant Phase II Trial of ZD1839 (Iressa) and Tamoxifen in Inoperable Locally Advanced HER2-Overexpressing, ER-Positive Breast Cancer Patients: Biologic Correlative Study (AZ #1839US/0303)
Status: Enrolling
Updated: 7/27/2015
Baylor Breast Center
mi
from
Houston, TX
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Columbia University Medical Center
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  7/28/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Aflibercept for Relapsed Multiple Myeloma
A Phase 2 Study of Aflibercept for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 7/28/2015
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials